Sofosbuvir Plus Daclatasvir in Chronic Hepatitis C Genotype 3 Naïve Patients

Abstract

Objective: To see the response rate of chronic hepatitis C Genotype 3 Naive patients to combination of sofosbuvir and daclatasvir.

Study Design: Prospective observational study

Place and Duration of Study: This study was conducted at the Hepatitis control programme, Medical B unit, Mardan medical complex teaching hospital Mardan from August 2017 to July 2018.

Materials and Methods: Seventy adult eligible both male and female Hepatitis C genotype 3 Naïve patients were included in the study. Sofosbuvir 400mg and Daclatasvir 60mg daily for 12 weeks were given to patients. Patients were tested for absence of detectable HCV RNA by PCR at the end of treatment and 12 weeks after the completion of treatment to look for sustained virological response at 12 weeks.

Results: A total seventy chronic Hepatitis C genotype 3 naive patients received treatment with sofosbuvir 400mg and Daclatasvir 60mg for 12 weeks .All patients completed treatment. Out of seventy patients, thirty nine (55.71%) were female and thirty one (44.29%) were male. The average age of the patients included in the study was 45.6 years. Patients were classified on the basis of APRI score into two categories. In 52 (74.28%) patients the APRI score was <2 and in 18(25.72%) patients the APRI was > 2, which shows cirrhosis. The end of treatment response was 98.57 %( 69).Only one patient was non responder. The sustained virological response rate was 97.1 %( 67) and only two (2.9%) patients were relapsed. Both patients have APRI score >2 were cirrhotic in relapse group. The overall response rate in cirrhosis liver was 88.8 %( 16).

Conclusion: Combination of sofosbuvir plus Daclatasvir for 12 weeks in chronic hepatitis C naive patients was associated with high rates of sustained virological response at 12 weeks.